Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New breast cancer study shows hormonal therapy not enough

09.12.2004


Many postmenopausal women with hormone-dependent breast cancer (requires estrogen and/or progesterone to grow) may be undertreated if they do not receive chemotherapy in addition to hormonal therapy after surgery, according to a Loyola University Health System, Maywood, Ill., study.

Loyola’s Dr. Kathy S. Albain presented the results of a 10-year follow-up of The Breast Cancer Intergroup of North America Trial 0100 at the late breaking session of the San Antonio Breast Cancer Symposium annual meeting here today. "The research shows that, in many cases, tamoxifen or other hormonal therapy alone is not optimal," said principal investigator and first author Albain, professor, division of hematology/oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Ill. "Overall, chemotherapy helped stop the cancer from recurring in postmenopausal women with receptor-positive breast cancer that has spread to the lymph nodes," said Albain. "This survival advantage was greatest when tamoxifen followed chemotherapy, rather than given concurrently.

"Ten-year disease-free-survival estimates were 48 percent for those treated with tamoxifen alone; 53 percent for concurrent chemohormonal therapy; and 60 percent for sequential therapy," said Albain, director, Breast Research Program; co-director of the multidisciplinary Breast Oncology Center; and director of the Thoracic Oncology Program, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Ill.



Albain and colleagues conducted a 10-year follow-up of 1,477 patients. A total of 550 patients received concurrent chemohormonal therapy (CAFT) (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen); another 566 patients received sequential chemohormonal therapy (CAF-T); and 361 patients received tamoxifen alone. "Long-term follow-up of this large North American trial confirms that chemotherapy benefits postmenopausal women with hormone-dependent breast cancer," said Albain. "We discovered that women with very high levels of estrogen receptor in their tumors can probably avoid chemotherapy, but those with lower or intermediate levels benefit from it over and above tamoxifen.

A second aspect of this study explored the use of various molecular markers measured on the breast tumor to predict the added value of chemotherapy. The purpose of this was to determine if the individual’s biologic profile on an individual tumor enables us to tailor therapy more specifically. "These results will help current breast cancer treatment in that we are moving to regimens tailored to the specific individual’s cancer and it will stimulate future research," said Albain.

Co-authors of the study are K. S. Albain; W. Barlow; F. O’Malley; K Siziopikou; I-T Yeh; P. Ravdin; D. Lew; W. Farrar; G. Burton; S. Ketchel; C. Cobau; E. Levine; J. Ingle; K. Pritchard; A. Lichter; D. Schneider; M. Abeloff; I. C. Henderson; L. Norton; D. Hayes; S. Green; R. Livingston; S. Martino; C. K. Osborne; and D. C. Allred, The Breast Cancer Intergroup of North America, Loyola University Chicago Stritch School of Medicine, Maywood, Ill.

For more information on Loyola University Health System, log onto http://www.luhs.org

The 27th Annual San Antonio Breast Cancer Symposium meeting at the Henry B. Gonzalez Convention Center, San Antonio, Tex., runs through December 11, 2004.

Joanne Swanson | EurekAlert!
Further information:
http://www.lumc.edu
http://www.luhs.org

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Getting electrons to move in a semiconductor

25.04.2018 | Physics and Astronomy

Reconstructing what makes us tick

25.04.2018 | Physics and Astronomy

Cheap 3-D printer can produce self-folding materials

25.04.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>